Glaukos Reports Record Q1 2025 Net Sales Growth

Glaukos ( (GKOS) ) just unveiled an update.

Glaukos Corporation announced its financial results for the first quarter of 2025, reporting record net sales of $106.7 million, a 25% increase from the previous year. The company reaffirmed its 2025 net sales guidance and highlighted its strong start to the year, driven by successful execution of strategic plans and advancements in its pipeline of novel technologies.

Spark’s Take on GKOS Stock

According to Spark, TipRanks’ AI Analyst, GKOS is a Neutral.

Glaukos’ overall score reflects its strong revenue growth and improved financial leverage, offset by persistent operational and cash flow challenges. The bearish technical indicators and high valuation relative to earnings further weigh on the score. Positive elements from the earnings call, such as record sales growth, provide some optimism, but significant risks remain.

To see Spark’s full report on GKOS stock, click here.

More about Glaukos

Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) and markets the only FDA-approved corneal cross-linking therapy for keratoconus.

YTD Price Performance: -37.33%

Average Trading Volume: 985,096

Technical Sentiment Signal: Hold

Current Market Cap: $5.36B

Find detailed analytics on GKOS stock on TipRanks’ Stock Analysis page.